Prelude Therapeutics Inc. described the discovery of PRT-3789, a first-in-human, highly potent and selective SMARCA2-targeted protein degrader, for the potential treatment of cancer.
Fibroblast activation protein (FAP) is a serine protease, the expression of which increases with pathogenic fibroblasts in the fibrotic liver during metabolic dysfunction-associated steatohepatitis (MASH) and might induce fibrosis by cleaving several proteins that regulate extracellular matrix turnover and metabolism, including α2-antiplasmin (α2-AP) and fibroblast growth factor 21 (FGF21). Astrazeneca plc recently presented new results on their research regarding their oral small-molecule FAP inhibitor, AZD-2389, as a candidate drug for treating MASH.
At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ligand-directed degrader (LDD) of B-cell lymphoma 6 protein (BCL6), BMS-986458, for the treatment of B-cell non-Hodgkin lymphoma.
In the brain, molecular information is transmitted between cells through neural circuits. Synapses establish connections between the pathways that run from one area to another, allowing the most complex organ in the body to fulfill different functions. Cells and neural circuits are the basic biological elements in the study of mental illness. However, the scientific community still does not know how to interpret their role in neuropsychiatric disorders.
Previous studies have shown that protein expression of DOCK7 is increased in skeletal muscle biopsies from patients with Duchenne muscular dystrophy (DMD), leading researchers from the University of Alabama at Birmingham and affiliated organizations to assess the functional impact of DOCK7 on normal muscle and embryonic development of zebrafish.
Alzamend Neuro Inc. recently presented pharmacokinetic data for the lithium-based sparing therapy AL-001, a lithium salicylate/L-proline co-crystal, in 5XFAD mice, a murine model of Alzheimer’s disease (AD).
Researchers from the University of Queensland recently provided details on the discovery and preclinical characterization of a new hematopoietic prostaglandin D2 synthase (HPGDS) inhibitor, CLS-189, being developed for the treatment of Duchenne muscular dystrophy (DMD).
At this week’s American Chemical Society Spring meeting, Galderma SA reported the discovery of novel, oral and selective macrocyclic inhibitors of protein kinase C θ (PKCθ) for the potential treatment of atopic dermatitis (AD) and psoriasis.
Researchers from Chinese Academy of Sciences detailed the creation of a new dextran sulfate sodium (DSS)-based mouse model of immune checkpoint blockade (ICB) therapy-associated colitis.
Precision Biosciences Inc. recently presented a new gene-editing approach, PBGENE-DMD, which could allow life-long benefits to patients with Duchenne muscular dystrophy (DMD).
RSS
